Precipitate formed by thiopentone and vecuronium causes pulmonary embolism
Abstract
Purpose
To examine the effects of a bolus injection of the precipitate formed by thiopentone and vecuronium on the pharmacokinetic behaviour of thiopentone, cardiopulmonary physiology, and lung histology.
Methods
Of 16 female rabbits (2.9 to 3.1 kg), eight were injected with a precipitate formed by a mixture of 5 mg·kg−1 thiopentone and 0.67 mg·kg−1 vecuronium via the external jugular vein. Eight control rabbits were injected with 5 mg·kg−1 thiopentone alone. Plasma thiopentone concentration, systolic arterial pressure and PaO2 were measured for 60 min after injection. Histological changes in the lungs were evaluated at one and 60 min.
Results
Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 ± 4.5 vs 17.0 ± 1.6 μg·ml,P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 ± 8.5 vs 21.7 ± 8.2 min.P < 0.05) and the area under the time concentration curve was similar between the two groups. However, the mean residence time was 28% longer in the precipitate group than in controls (P < 0.05). The PaO2 was lower in the precipitate group than in controls one minute after injection (431 ± 27 vs 464 ± 18 mmHg,P < 0.05) but not subsequently. Histologically, crystals (30–150 μm in diameter) obstructed small arteries in the lungs at one minute but not at 60 min after injection.
Conclusion
Intravenous injection of precipitate causes pulmonary microembolism, with a small transient decrease in PaO2
Keywords
Bolus Injection Thiopental Thiopentone Vecuronium Systolic Arterial PressureRésumé
Objectif
Évaluer l’effet de l’injection en bolus du précipité formé par le thiopental et le vécuronium sur la pharmacocinétique du thiopental, sur la physiologie cardio-pulmonaire et sur l’histologie pulmonaire.
Méthodes
D’un groupe de 16 lapins femelles (2,9 à 3, 1 kg), 8 ont reçu IV par la jugulaire externe un précipité composé de 5 mg·kg−1 de thiopental et de 0,67 mg·kg−1 de vécuronium, alors que les 8 témoins n’ont reçu que du thiopental à la dose de 5 mg·kg−1. Durant les 60 minutes suivant l’injection on a mesuré la concentration plasmatique de thiopental, la pression artérielle systolique et la PaO2. Les changements histologiques du poumon ont été évalués à une minute et à 60 min.
Résultats
La concentration sanguine maximale de thiopental était plus basse dans le groupe précipité que dans le groupe témoin (12,9 ± 4,5 vs 17,0 ± 1,6 μg·ml−1,P < 0,05); cependant, la demi-vie du thiopental dans le groupe précipité était plus longue (32,3 ± 8,5 vs 21,7 ± 8,2 min,P < 0,05) et la surface sous la courbe temps/concentration était similaire pour les deux groupes. Cependant le temps de rétention moyen était de 28% plus long dans le groupe précipité (P < 0,05). La PaO2 était plus basse dans le groupe précipité à 1 minute après l’injection (431 ± 27 vs 464 ± 18 mmHg,P < 0,05) mais non par la suite. Histologiquement, des cristaux (30–150 μm de diamètre) obstruaient les petites artères des poumons à 1 minute après l’injection, mais n’étaient plus visibles à 60 min.
Conclusion
L’injection intraveineuse de précipité cause des microembolies pulmonaires avec une baisse transitoire de la PaO2.
References
- 1.Taniguchi T, Yamamoto K, Kobayashi T. The precipitate formed by thiopentone and vecuronium. Can J Anaesth 1996; 43: 511–3.PubMedGoogle Scholar
- 2.Blackman GL, Jordan GJ. Analysis of thiopentone in human plasma by high-performance liquid chromatography. J Chromatogr 1978; 145: 492–5.PubMedCrossRefGoogle Scholar
- 3.Hull CJ. General principles of pharmacokinetics.In: Prys-Roberts C, Hug CC Jr (Eds.). Pharmacokinetics of Anaesthesia. Oxford: Blackwell Scientific Publications, 1984: 1–24.Google Scholar
- 4.Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and Applications, 3rd ed. Philadelphia: Lea & Febiger, 1995: 469–89.Google Scholar
- 5.Collins JL, Lutz RJ.In vitro study of simultaneous infusion of incompatible drugs in multilumen catheters. Heart Lung 1991; 20: 271–7.PubMedGoogle Scholar
- 6.Allen LV Jr, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 1977; 34: 939–43.PubMedGoogle Scholar
- 7.Lutz RJ, Dedrick RL, Boretos JW, Oldfield EH, Blacklock JB, Doppman JL. Mixing studies during intracarotid artery infusions in an in vitro model. J Neurosurg 1986; 64: 277–83.PubMedCrossRefGoogle Scholar
- 8.Tarr BD, Yalkowsky SH. A new parenteral vehicle for the administration of some poorly water soluble anticancer drugs. J Parenter Sci Technol 1987; 41: 31–3.PubMedGoogle Scholar
- 9.Yalkowsky SH, Valvani SC, Johnson BW.In vitro method for detecting precipitation of parenteral formations after injection. J Pharm Sci 1983; 72: 1014–7.PubMedCrossRefGoogle Scholar
- 10.Schroeder HG, DeLuca PP. Particulate matter assessment of a clinical investigation on filtration and infusion phlebitis. Am J Hosp Pharm 1976; 33: 543–6.PubMedGoogle Scholar
- 11.Flynn GL. Solubility concepts and their applications to the formulation of pharmaceutical systems. J Parenter Sci Technol 1984; 38: 202–9.PubMedGoogle Scholar
- 12.Benumof JL. Respiratory physiology and respiratory function during anesthesia.In: Miller RD (Ed.). Anesthesia, 4th ed. New York: Churchill Livingstone, 1994: 594–600.Google Scholar